Navigation Links
Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
Date:11/2/2010

ovisions of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, statements relating to the anticipated initiation of Anthera's clinical studies, anticipated duration and expected results of these studies, and the progression of Anthera's products through future stages of clinical development. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the Securities and Exchange Commission, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510-856-5586.ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanySTATEMENT OF OPERATIONS(unaudited)Three Months Ended September 30,Nine Months Ended September 30,2010200920102009OPERATING EXPENSE:  Research and development

$
,885,125$
2,525,948$
8,565,088$
7,727,129  General and administrative

1,510,021884,9084,244,0002,730,482Total operating expense

8,395,1463,410,85622,809,08810,457,611LOSS FROM OPERATIONS:

(8,395,146)(3,410,856)(22,809,088)(10,457,611)OTHER INCOME (EXPENSE):Interest and other income

61,606-76,56221,559Interest and other expense

-(193,556)(4,641,169)(289,776)Total other income (expense)

61,606(193,556)(4,564,607)(268,217)NET LOSS

$  (8,333,540)$   (3,604,412)$  (27,373,695)$   (10,725,828)Net loss per share--basic and diluted

$
(0.36)$
(2.37)$
(1.40)$
(7.16) Weighted-average number of shares used in
per share
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
2. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
3. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
4. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
5. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
6. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
8. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
9. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
11. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015  ULURU Inc. (OTCQB: ULUR) announced today ... the appointment of Bradley J. Sacks to the ... of Directors has determined that the 2015 Annual Meeting of ... at 10:00 a.m., Central Daylight Time at the offices of ... 75001. In accordance with the provisions of ...
(Date:7/28/2015)... 28, 2015  Alere Inc. (NYSE: ALR ), ... it will release its financial results for the second ... a conference call beginning at 8:30 a.m. ET on ... provide business updates. The conference call ... of Alere,s website, or accessed directly through the following ...
(Date:7/28/2015)... , July 28, 2015  Cepheid (Nasdaq: ... flexible and portable clinical molecular diagnostic system designed ... Care market.  At just 9 inches tall, and ... run the same high quality PCR-based Xpert® cartridges ... highly accurate clinical molecular diagnostic tests to be ...
Breaking Medicine Technology:ULURU Inc. Announces The Schedule For The 2015 Annual Meeting Of Stockholders And The Appointment Of Bradley J. Sacks To The Board Of Directors 2ULURU Inc. Announces The Schedule For The 2015 Annual Meeting Of Stockholders And The Appointment Of Bradley J. Sacks To The Board Of Directors 3Alere to Report Second Quarter 2015 Financial Results on August 4, 2015 2World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 2World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 3World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 4
... Feb. 1, 2012  Continuing its mission to give back ... $75,000 in an auction on January 16, 2012 benefiting ... (Photo: http://photos.prnewswire.com/prnh/20120201/NY45473 ) (Logo: ... its annual auction during VWR International, LLC,s North American ...
... Feb. 1, 2012 February is American Heart Month ... her daughter Eve, reflect on their family history of ... That,s why they are teaming up with the makers ... Women with Heart Disease, to raise $100,000 for the ...
Cached Medicine Technology:The VWR Foundation Auction Raises $75,000 for Children's National Medical Center 2In Honor of American Heart Month, Joy Behar & Daughter Eve Call on Women to Take the ProHeart Pledge on Facebook 2In Honor of American Heart Month, Joy Behar & Daughter Eve Call on Women to Take the ProHeart Pledge on Facebook 3In Honor of American Heart Month, Joy Behar & Daughter Eve Call on Women to Take the ProHeart Pledge on Facebook 4
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... Bipolar disorder ... times a day to a few times a year. The World Health Organization (WHO) ... by the National Institute of Mental Health reveals that the United States has the ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new Taiwanese study ... they are in the general population. Surviving Mesothelioma has just posted an article ... Researchers at Taiwan’s National Health Research Institutes and three Taiwanese universities evaluated the ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... A new ... May Easy Fibromyalgia, Study Says " sheds light on a possible new treatment option ... of two months of regular HBOT sessions, at least five per week, patients experienced ...
(Date:7/28/2015)... ... July 28, 2015 , ... There has been much discussion in ... bridges and railroads, often overlooked is the over 740,000 miles of municipal sewer ... into sewage treatment facilities. According to the American Society of Civil Engineers , ...
(Date:7/28/2015)... ... July 28, 2015 , ... Please join us for the 5th Annual Step for Hope ... at Gary Avenue and Lies Road in Carol Stream. All are welcome. , Now ... provide education and help to support individuals and families affected by a brain aneurysm. ...
Breaking Medicine News(10 mins):Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2
... Rebuild Schools and Clinics, LOS ANGELES, May 14 ... relief agency,today announced that it is responding with aid ... earthquake has mobilized relief agencies from,around the world and ... the call., The Chinese Army is taking the ...
... Offers Tips to Help Make Healthy Choices on the ... Swimsuit season is right around the,corner and for many ... though, cutting back on calories and finding time to ... CareerBuilder.com survey reports,that 45 percent of workers have gained ...
... by Johns Hopkins doctors has fine-tuned the dosage and ... patients with strokes caused by bleeding within the brain. ... Stroke Conference in Nice, France, has been shown to ... typically lethal subset of stroke. , "We,ve gone from ...
... children can be picky eaters,spooked by strong flavors or ... the taste of the pickiest eaters. But just because ... family can,t,enjoy something with more zip. To help parents ... without spending all night in the kitchen,Mealtime.org has devised ...
... Stable Treatment for Hemophilia With ... Patients, PRINCETON, N.J., May 13 Novo ... Administration (FDA) has approved,NovoSeven(R) RT (Coagulation Factor VIIa ... recombinant product available,for the treatment of bleeding episodes ...
... Ill., May 13 Z Trim Holdings, Inc.,(Amex: ... statements,for the fiscal year ended December 31, 2007 contained ... accounting,firm, Blackman Kallick LLP. This announcement is being made ... which requires separate disclosure,of receipt of an audit opinion ...
Cached Medicine News:Health News:Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds 2Health News:Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds 3Health News:Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds 4Health News:Researchers fine-tune clot-busting treatment for bleeding in brain 2Health News:Personalized Plates for Picky Palates: Moms can Satisfy all With One Recipe, Four Ways 2Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 2Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 3Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 4Health News:Z Trim Holdings, Inc. Audit Report Contains 'Going Concern' Qualification 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: